Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Bosentan on Lurbinectedin Pharmacokinetics
NCT05072106Phase 1Completed
- Sponsor
- PharmaMar
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lurbinectedin in solid tumor (advanced stage) (2 arms), sponsored by PharmaMar. Primary endpoints: Dose-normalized Maximum Observed Plasma Concentration of Total Lurbinectedin and Dose-normalized Area Under the Plasma Concentration-time Profile From Time Zero to Extrapolated Infinity. Started Jan 2021; status: completed.
02
Drugs
lurbinectedin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05072106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072106.